Pharmaceutical Industry Today
Global Paclitaxel Market Size, Industry Analysis, Segmentation and Forecast to 2025
Global Paclitaxel Market is a detailed report, which presents a combination of industry knowledge and research expertise based on regions too. This report delivers the market trends along with the market size for every individual sector.
Published 22 June 2018
This report studies the global Paclitaxel industry status, China market entry and growth opportunity, focuses on the Chinese local and International manufacturers, analyzes the China market competition landscape, market size (value and volume), opportunity and challenge, risk and entry barriers.
Paclitaxel is a mitotic inhibitor used in Cancer chemotherapy; Paclitaxel was discovered in 1962 as a result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it "taxol".
Request Sample Copy of the Report @ https://www.qyresearch.com/sample-form/form/524798/global-paclitaxel-industry-research-china-market
Paclitaxel is a white crystalline powder, odorless and tasteless. It is insoluble in water and soluble in chloroform, acetone and other organic solvents.
Paclitaxel is widely sales for Ovarian Cancer, Cervical Cancer, Breast Cancer and Others. The most proportion of Paclitaxel is sales in Ovarian Cancer, and the consumption proportion is about 46% in 2017.
North America is the largest consumption place, with a consumption market share nearly 52.3% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 19.6%, China is also an important sales regions for the Paclitaxel.
The global Paclitaxel market is valued at 79 million USD in 2017 and is expected to reach 160 million USD by the end of 2025, growing at a CAGR of 9.4% between 2018 and 2025.
Ask for Discount on Research Report@ https://www.qyresearch.com/request-discount/form/524798/global-paclitaxel-industry-research-china-market
This research report categorizes the China and global Paclitaxel market by type, end-use industry, and region.
International Manufacturers Covered
QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert’s resources (included energy automotive chemical medical ICT consumer goods etc.
Contact US
QY Research, INC.
17890 Castleton,
Suite 218,
City of industry, CA - 91748
USA: +1 626 295 2442
Email – inquiry@qyrsearch.com
Web – www.qyresearch.com
Paclitaxel is a mitotic inhibitor used in Cancer chemotherapy; Paclitaxel was discovered in 1962 as a result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it "taxol".
Request Sample Copy of the Report @ https://www.qyresearch.com/sample-form/form/524798/global-paclitaxel-industry-research-china-market
Paclitaxel is a white crystalline powder, odorless and tasteless. It is insoluble in water and soluble in chloroform, acetone and other organic solvents.
Paclitaxel is widely sales for Ovarian Cancer, Cervical Cancer, Breast Cancer and Others. The most proportion of Paclitaxel is sales in Ovarian Cancer, and the consumption proportion is about 46% in 2017.
North America is the largest consumption place, with a consumption market share nearly 52.3% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 19.6%, China is also an important sales regions for the Paclitaxel.
The global Paclitaxel market is valued at 79 million USD in 2017 and is expected to reach 160 million USD by the end of 2025, growing at a CAGR of 9.4% between 2018 and 2025.
Ask for Discount on Research Report@ https://www.qyresearch.com/request-discount/form/524798/global-paclitaxel-industry-research-china-market
This research report categorizes the China and global Paclitaxel market by type, end-use industry, and region.
International Manufacturers Covered
- Phyton
- ScinoPharm
- Novasep
- Samyang
- Polymed
- TAPI (Teva)
- Fresenius-kabi
- Huiang biopharma
- Southpharma
- Yunnan Hande
- Hainan Yew Pharm
- Jiangsu Yew Biotechnology
- Natural Paclitaxel API
- Semi-synthetic Paclitaxel API
- Ovarian Cancer
- Cervical Cancer
- Breast Cancer
- Other
- United States
- Europe
- Japan
- Korea
- Southeast Asia
- India
- Central & South America
- Middle East & Africa
QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert’s resources (included energy automotive chemical medical ICT consumer goods etc.
Contact US
QY Research, INC.
17890 Castleton,
Suite 218,
City of industry, CA - 91748
USA: +1 626 295 2442
Email – inquiry@qyrsearch.com
Web – www.qyresearch.com
Share on Social Media
Other Industry News
Ready to start publishing
Sign Up today!
